Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Coagulation laboratory tests


Reviewer: Nat Pernick, M.D. (see Reviewers page)
Revised: 15 March 2012, last major update March 2012
Copyright: (c) 2002-2012, PathologyOutlines.com, Inc.


● Oral anti-coagulant (also rivaroxaban, apixaban) with minimal food and drug interactions that does not require coagulation monitoring
● Drug is very expensive, and is affected by humidity (Wikipedia)
● Dabigatran etexilate is prodrug of dabigatran, a direct thrombin inhibitor
● Alternative to warfarin for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (J Clin Pharmacol 2012 Jan 31 [Epub ahead of print], J Med Econ 2012 Mar 7 [Epub ahead of print]) or venous thromboembolism (N Engl J Med 2009;361:2342, Vasc Health Risk Manag 2012;8:45)
● Good patient compliance (Orthop Traumatol Surg Res 2012 Mar 2 [Epub ahead of print])
● INR levels are not necessary, and are substantially higher using Hemochron Jr. point-of-care device compared with laboratory values (Am J Med 2012 Feb 3 [Epub ahead of print])
● Can use HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran (Blood Coagul Fibrinolysis 2012;23:138)
● Contraindications: nonvalvular atrial fibrillation patients with renal insufficiency (Rinsho Shinkeigaku 2011;51:1004), INR 2.0 or greater, age 80 years or greater (N Engl J Med 2012;366:864)



Structure and site of inhibition in coagulation cascade

End of Coagulation > Coagulation laboratory tests > Dabigatran

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).